Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Baudin, E.
Right arrow Articles by Schlumberger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baudin, E.
Right arrow Articles by Schlumberger, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:S79-S82, 2001
© 2001 European Society for Medical Oncology

Impact of chromogranin A measurement in the work-cup of neuroendocrine tumors

E. Baudin1, J. M. Bidart2, A. Bachelot1, M. Ducreux3, D. Elias4, P. Ruffié3 and M. Schlumberger1

1 Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave-Roussy Villejuif, France
2 Department of Clinical Biology, Institut Gustave-Roussy Villejuif, France
3 Department of Medicine, Institut Gustave-Roussy Villejuif, France
4 Department of Surgery, Institut Gustave-Roussy Villejuif, France

Correspondence to: Dr E. Baudin, Institut Gustave-Roussy 39 rue Camille Desmoulins 94805 Villejuif Cedex France E-mail: baudin{at}igr.fr

Since the development of the first immunoassay for circulating chromogranin A in 1984, a lot of studies have evaluated its clinical impact in neuroendocrine tumors. Initially studied in pheochromocytoma patients, the clinical impact of chromogranin A has rapidly extended to most neuroendocrine tumours, sometimes in combination with other eutopic or ectopic secretions. In our experience, CgA demonstrates a variable sensitivity between NET primary and a high specificity. Our results suggest that CgA should be routinely screened in foregut-derived NET and abandoned in, the routine screening of medullary thyroid carcinoma. In addition, in phaeochromocytoma and ileum-NET patients, CgA demonstrates a comparable sensitivity with urinary reference markers and its impact on the followup will form a key point when recommending routine screening. Both tumor burden and secretory activity should be taken into account when interpreting CgA results.

chromogranin A, neuroendocrine tumors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
M. C. Zatelli, M. Torta, A. Leon, M. R. Ambrosio, M. Gion, P. Tomassetti, F. De Braud, G. Delle Fave, L. Dogliotti, E. C d. Uberti, et al.
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study
Endocr. Relat. Cancer, June 1, 2007; 14(2): 473 - 482.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.